-
Product Insights
NewNet Present Value Model: Inhibrx Inc’s INBRX-101
Empower your strategies with our Net Present Value Model: Inhibrx Inc's INBRX-101 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence. emphysema. The therapeutic candidate comprises of alpha-1 antitrypsin (AAT)-Fc fusion proteins and developed based...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAT-076 in Pain
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AAT-076 in Pain Drug Details:RMX-1001 is under development for the treatment of pain including cancer pain...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAT-009 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAT-009 in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.AAT-009 in Alzheimer's DiseaseDrug Details:AAT-009 is under development for the treatment of dementia...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belzutifan in Pancreatic Ductal Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Belzutifan in Pancreatic Ductal Adenocarcinoma Drug Details: Belzutifan (Welireg), is an inhibitor of hypoxia-inducible factor-2a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IGM-7354 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IGM-7354 in Solid Tumor Drug Details: IGM-7354 is under development for the treatment of relapsed...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fazirsiran Sodium in Alpha-1 Antitrypsin Deficiency (A1AD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Fazirsiran Sodium in Alpha-1 Antitrypsin Deficiency (A1AD)Drug Details:ARO-AAT is under development for the treatment of liver...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VX-634 in Alpha-1 Antitrypsin Deficiency (A1AD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VX-634 in Alpha-1 Antitrypsin Deficiency (A1AD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.VX-634 in Alpha-1 Antitrypsin Deficiency (A1AD)Drug Details:VX-634 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – LN-145S1 in Osteosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LN-145S1 in Osteosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LN-145S1 in Osteosarcoma Drug Details: LN-145-S1 is under development for the treatment of...
-
Product Insights
Neurological Diagnostic and Monitoring Equipment Pipeline by Development Stages, Segments, Countries, Regulatory Path and Key Companies
Neurological Diagnostic and Monitoring Equipment Pipeline Market Report Overview The Neurological Diagnostic and Monitoring Equipment pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segments ·       Electroencephelographs (EEG) ·       ICP Monitoring Devices ·       Electrical Activity Testing ·       ...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Alpha-1 Proteinase Inhibitor (Human) Second Generation in Alpha-1 Antitrypsin Deficiency (A1AD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Alpha-1 Proteinase Inhibitor (Human) Second Generation in Alpha-1 Antitrypsin Deficiency (A1AD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Alpha-1 Proteinase Inhibitor (Human) Second...